Doptelet cost-effective, avoids transfusions for CLD-related thrombocytopenia

Treatment with Doptelet was cost-effective for the treatment of thrombocytopenia in patients with chronic liver diseases compared with other treatment options, according to data presented at the American Society of Hematology meeting.
The study compared Doptelet (avatrombopag, Dova Pharmaceuticals), an oral thrombopoietin receptor agonist approved by both the FDA and the European Medicines Agency (EMA) for treatment of thrombocytopenia in adults with CLD who are scheduled to undergo a procedure, with platelet transfusion and Mulpleta (lusutrombopag, Shinogi).
“The results showed that the

Source link

Related posts

Transcriptional study of appetite regulating genes in the brain of zebrafish (Danio rerio) with impaired leptin signalling


Institutions use transarterial radioembolization for pediatric liver cancer


Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy